At AI Dubliners, we do not just feature a company once.
We follow companies over time, because the Irish AI ecosystem is not only made up of new names. It is also shaped by companies whose work becomes more important as they grow.
Deciphex is one of those companies.
When we first featured Deciphex in November 2025, what stood out was not simply that it uses AI. It was that the company is applying AI to one of healthcare’s most important bottlenecks: pathology capacity.
That challenge has not gone away. If anything, it has become more urgent. Healthcare systems continue to face rising case volumes, more complex diagnostics and ongoing shortages of specialist pathologists.
This is where Deciphex’s work remains especially relevant.
The company has spent years building AI-powered digital pathology solutions designed to improve pathology workflows across both clinical diagnostics and research. Recent developments suggest that this journey is continuing with strong momentum.
One of the clearest recent signals came in March 2026, when Patholytix 4.0 introduced native DICOM support for the digital archiving and reconstruction of GLP-regulated drug safety studies. That may sound like a technical update, but it points to something larger: pathology, much like radiology before it, is moving toward more standardised, interoperable and digitally mature workflows.
There are other notable signals too.
Diagnexia, part of the broader Deciphex group, achieved UKAS accreditation for its Oxford histopathology laboratory and digital pathology services. The company has also remained visible across scientific and pathology communities, continuing to share expertise on digital pathology, workflow integration and AI-assisted diagnostics.
Another point that stands out is the company’s emphasis on trust and governance alongside innovation. In a field as high-stakes as healthcare, that matters. Because AI does not create real value in medicine unless it is both useful and trusted.
What makes Deciphex especially interesting is that it is not only building AI tools. It is combining a global network of expert pathologists with AI to address a real and growing healthcare capacity problem.
That means viewing Deciphex purely as an AI company may not tell the full story.
It is also one of the companies helping shape the future infrastructure of healthcare.
At AI Dubliners, we continue to follow Deciphex closely for exactly that reason.
Because sometimes the impact of AI does not appear in headlines about new models.
Sometimes it appears in faster diagnoses, stronger healthcare systems and better patient outcomes.
